FDA Approved: DAYVIGO — Supplemental Application (Eisai Inc.)

View source ↗

Summary

FDA documents a supplemental labeling application for DAYVIGO (lemborexant) by Eisai Inc., likely to modify the drug’s labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insomnia

Drugs mentioned

• Dayvigo (lemborexant)

Snippet

SUPPL AP for DAYVIGO (LEMBOREXANT)